<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04437303</url>
  </required_header>
  <id_info>
    <org_study_id>NL73805.100.20</org_study_id>
    <nct_id>NCT04437303</nct_id>
  </id_info>
  <brief_title>Periprocedural Continuation Versus Interruption of Oral Anticoagulant Therapy and Protamine Use During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)</brief_title>
  <official_title>Periprocedural Continuation Versus Interruption of Oral Anticoagulant Therapy and Protamine Use During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) is a rapidly growing treatment option for
      patients with aortic valve stenosis. Stroke is a feared complication of TAVI, with an
      incidence of around 4-5% in the first 30 days. Up to 50% of patients undergoing TAVI have an
      indication for oral anticoagulants (OAC) mostly for atrial fibrillation. OAC use during TAVI
      could increase bleeding complications, but interruption during TAVI may increase the risk for
      thromboembolic events (i.e. stroke, systemic embolism, myocardial infarction). Recent
      observational data suggest that periprocedural continuation of OAC is safe and might decrease
      the risk of stroke. Beside the potential reduction of thromboembolic events, continuation of
      OAC is associated with an evident clinical ancillary benefit for patients and staff. Since
      periprocedural OAC interruption not infrequently leads to misunderstanding and potentially
      dangerous situations, when patients are not properly informed before hospital admission or
      may experience difficulties with the interruption regimen.

      Hypothesis:

      Periprocedural continuation of oral anticoagulants is safe and might decrease thromboembolic
      complications without an increase in bleeding complications at 30 days
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net clinical benefit</measure>
    <time_frame>30 days</time_frame>
    <description>A composite of cardiovascular mortality, stroke, myocardial infarction, major vascular complications and major, disabling and life-threatening bleeding complications at 30 days post TAVI as defined by the VARC-2 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of stroke, transient ischemic attack, systemic embolism, distal embolization, myocardial infarction, and cardiovascular death not caused by bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding and vascular access site complications</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of bleeding and vascular access site and access-related complications (except distal embolization and systemic embolism)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early safety as defined by Valve Academic Research Consortium 2 criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause mortality, all stroke, life-threatening bleeding, stage 2 or 3 acute kidney injury, coronary artery obstruction requiring intervention, major vascular complication, and valve-related dysfunction requiring repeat procedure (balloon valvuloplasty or valve replacement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy as defined by Valve Academic Research Consortium 2 criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause mortality, all stroke, hospitalizations for valve related symptoms or worsening congestive heart failure, New York Heart Association class for heart failure 3/4, and valve-related dysfunction (mean aortic valve gradient &gt;=20 mmHg, effective orifice area (EOA) &lt;=0.9-1.1 cm^2 and/or Doppler velocity index (DVI) &lt;0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Short Form-12 Questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Toronto Aortic Stenosis Questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke and transient ischemic attack</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding classification as defined by the International Society of Thrombosis and Haemostasis criteria</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding classification as defined by Thrombolysis In Myocardial Infarction criteria</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding classification as defined by Bleeding Academic Research Consortium criteria</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Primary endpoints at discharge</measure>
    <time_frame>Discharge</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association class for heart failure</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Device success as defined by Valve Academic Research Consortium 2 criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Absence or procedural mortality AND Correct positioning of a single prosthetic heart valve into the proper anatomical position AND Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, AND no moderate or severe prosthetic valve regurgitation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time-related valve safety as defined by Valve Academic Research Consortium 2 criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of:
Structural valve deterioration
(valve-related dysfunction (mean aortic valve gradient &gt;=20 mmHg, effective orifice area (EOA) &lt;=0.9-1.1 cm^2 and/or Doppler velocity index (DVI) &lt;0.35 m/s, and/or moderate or severe prosthetic valve regurgitation)
(requiring repeat procedure)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thrombo-embolic events (e.g. stroke)
Bleeding (as defined by Valve Academic Research Consortium), unless clearly unrelated to valve therapy (e.g. trauma)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">858</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Stroke</condition>
  <condition>Bleeding</condition>
  <condition>Vascular Complications</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Thrombosis Embolism</condition>
  <arm_group>
    <arm_group_label>Continuation of oral anticoagulants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interruption of oral anticoagulants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuation of oral anticoagulants</intervention_name>
    <description>Oral anticoagulant treatment will not be interrupted before the procedure.</description>
    <arm_group_label>Continuation of oral anticoagulants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interruption of oral anticoagulants</intervention_name>
    <description>Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.
For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m^2 96 hours before procedure.
For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.
After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician.</description>
    <arm_group_label>Interruption of oral anticoagulants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned transfemoral transcatheter aortic valve implantation procedure

          -  Uses oral anticoagulation at screening

        Exclusion Criteria:

        Patients at high risk for thromboembolism for who interruption of oral anticoagulants is no
        option, i.e.:

          -  Mechanical heart valve prosthesis

          -  Intracardiac thrombus

          -  &lt; 3 months after venous thromboembolism

          -  &lt; 6 months after transient ischemic attack or stroke in patients with atrial
             fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurriën M ten Berg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Ziekenhuis Nieuwegein, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilbert Bor, MD</last_name>
    <phone>+31 (0)88 320 1241</phone>
    <email>w.bor@antoniusziekenhuis.nl</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>J.M. ten Berg</investigator_full_name>
    <investigator_title>Professor dr.</investigator_title>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Implantation (TAVI)</keyword>
  <keyword>Transcatheter Aortic Valve Replacement (TAVR)</keyword>
  <keyword>Aortic Valve Disease</keyword>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Stroke</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Vascular Complications</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Thrombosis Embolism</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Oral Anticoagulation</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Vitamin K Antagonist</keyword>
  <keyword>Direct Acting Oral Anticoagulants</keyword>
  <keyword>Protamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

